The venture capital arm of the New Jersey consumer products giant officially unveiled its JLABS@South San Francisco campus Monday. The 30,000-square foot incubator will eventually house up to 50 startups.
Blueprint Medicines has announced a strategic collaboration with Alexion to discover, develop...
The current GSK Opiates business including related manufacturing sites in Latrobe (Tasmania) and...
AstraZeneca today announced that it has completed the transaction to acquire the rights to...
Shares of Pacira Pharmaceuticals tumbled Monday after the company said regulators refused to grant a new marketing approval for its post-surgical pain drug Exparel.
Britain's GlaxoSmithKline PLC and Switzerland's Novartis AG have completed a three-part deal that will offer the British company's shareholders a 4 billion pound ($6.17 billion) windfall.
A Salt Lake City-based company has agreed to pay refunds to consumers who purchased its weight-loss tablets to settle a class-action lawsuit that claimed its advertising slogan, "Eat All You Want & Still Lose Weight," was deceptive.
Teva Pharmaceutical Industries today announced that it has signed an agreement to sell its Sellersville, Pennsylvania facility to G&W Laboratories, Inc. This sale supports its plans to streamline operations by reducing excess manufacturing capacity and is part of the company’s previously announced cost reduction program.
Endo International has entered into a definitive agreement with Boston Scientific, under which Boston Scientific will acquire Endo's American Medical Systems' (AMS) Men's and Prostate Health businesses for up to $1.65 billion, with $1.6 billion in cash payable at closing.
Cardinal Health today announced plans to acquire Johnson & Johnson's Cordis business, a global manufacturer of cardiology and endovascular devices, for $1.944 billion in cash, or approximately $1.594 billion, net of the present value of tax benefits.
The new agreement will take effect on April 1, 2015 and extend through June 2018. As part of the agreement, Cardinal Health will assume responsibility for the sourcing and distribution of branded and generic pharmaceuticals for PharMerica.
Bipartisan Act would preserve FDA user fees from sequestration.
A recent report from research firm GlobalData predicted Japan will see a "tepid" recovery in its pharmaceutical market over the next several years. The London-based firm estimates Japan’s pharmaceutical market will climb from $72.8 billion in 2013 to $79.8 billion by 2020, a Compound Annual Growth Rate of 1.3 percent.
South Carolina's high court says a Johnson & Johnson subsidiary should pay the state $136 million over deceptive drug marketing of an anti-psychotic drug.
Biota Pharmaceuticals has entered into a definitive agreement to acquire Anaconda Pharma, a privately-held biotechnology company based in Paris, France. Anaconda Pharma's lead candidate is AP611074, a patented, direct-acting antiviral in development.
President Barack Obama's health secretary told Congress Tuesday that she has no administrative actions available to fix the "massive damage to our health care system" that would result should the Supreme Court invalidate federal subsidies that help millions of Americans buy health care coverage.
The analysis by New York-based Persistence Market Research predicted Vitamin D supplements would lead the growth in the industry over that span. The report expects increasing geriatric populations, particularly in Asia, to bolster demand for Vitamin D.
Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones.
Baxter International announced today that Baxalta Incorporated, the biopharmaceutical company that is expected to separate from Baxter in mid-2015, will be headquartered in Northern Illinois at 1200 Lakeside Drive, Bannockburn, IL.
Valeant Pharmaceuticals International Inc. has agreed to buy Salix Pharmaceuticals Ltd. for about $10 billion in cash. The companies said Sunday that their boards of directors approved the transaction, which amounts to about $158 for each of Salix's outstanding shares.
NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas.
Mylan announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi and Harvoni for the treatment of chronic hepatitis C, in India.
Bristol-Myers Squibb and Flexus Biosciences announced today the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Flexus, a privately held biotechnology company focused on the discovery and development of novel anti-cancer therapeutics.
Officials said Thursday that San Francisco-based McKesson Corp. would occupy a new 340,000-square-foot distribution center in Clear Lake, ending a nearly yearlong mystery about the company's identity.
Under the terms of the agreement, NewLink Genetics will receive a payment of $20 million in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
Ferring Pharmaceuticals announced today that it has acquired the assets of BioSurface Engineering Technologies, Inc. (BioSET), including two phase III ready orthobiologic product candidates designed to improve bone repair.
The Chinese treatment market for colorectal cancer (CRC) will expand almost fourfold in value from an estimated $259 million in 2013 to $1.05 billion by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 15.1%, according to research and consulting firm GlobalData.
CVS Health Raises Concerns about the Potential Impact of New Class of Cholesterol Drugs on the Health Care SystemFebruary 18, 2015 8:30 am | News | Comments
Currently in development, PCSK9 (proprotein convertase subtilisin/kexin 9) enzyme inhibitors could successfully treat millions of Americans with high cholesterol, but at great cost to the health care system.
- Page 1